diabetes, metabolic syndrome and obesity : targets and therapy

[1] Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes.

[2] safety of high-dose daptomycin in patients with severe renal impairment

[3] prenatally programmed hypertension: role of maternal diabetes

[4] use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence

[5] Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: A pooled analysis of randomized controlled trials and real-world studies

[6] Pharmacokinetic-Pharmacodynamic (Dipeptidyl Peptidase-4 Inhibition) Model to Support Dose Rationale in Diabetes Patients, Including Those with Renal Impairment, for the Once-Weekly Administered Omarigliptin.

[7] Bortezomib in patients with renal impairment.

[8] Influence of renal impairment on myocardial function in outpatients with systolic heart failure: an echocardiographic and cardiac biomarker study.

[9] Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment

[10] safety of high-dose daptomycin in patients with severe renal impairment

[11] management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin

[12] pharmacokinetic profile of defibrotide in patients with renal impairment

[13] letter: economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients ( 2015;39:74-81)

[14] Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment

[15] Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double‐Blind Controlled Trial